Replies to post #2594 on Actinium Pharmaceuticals Inc (ATNM)

[cardmaster114]

- Dr. Helen Kotanides Vice President, Translational Research and Preclinical Development with 25 years of immunotherapy and biologics R&D expertise

- Dr. Monideepa Roy, Vice President, Corporate Development - R&D adds company building, research management and oncology R&D experience

NEW YORK, Sept. 27, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced multiple updates on its R&D capabilities. Actinium recently completed expansion of its New York City based research facilities to focus on the development of targeted radiotherapies for solid tumors and blood cancers and to investigate novel radiotherapy combinations with checkpoint inhibitors. Actinium has more than doubled its laboratory footprint and expanded its R&D capabilities. In addition to infrastructure, Actinium has increased its R&D team to include scientists with expertise across cancer biology, immunology, radiation sciences and chemistry including the appointment of Helen Kotanides, Ph.D., as Vice President, Translational Research and Preclinical Development and Monideepa Roy, Ph.D., as Vice President, Corporate Development - R&D to its R&D leadership team.